Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

A Great Start to 2020

A Great Start to 2020
January 16, 2020

If you missed it, before Christmas, we announced that Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, had been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35

MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35
December 19, 2019

Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.